HARMONY BIOSCIENCES HOLDINGS, INC. Federal Income Tax Expense (Benefit), Continuing Operations
HARMONY BIOSCIENCES HOLDINGS, INC. (HRMY) reported Federal Income Tax Expense (Benefit), Continuing Operations of $41.75 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Expense Statement › Income Tax
us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations · last filed 2026-02-24
- HARMONY BIOSCIENCES HOLDINGS, INC. federal income tax expense (benefit), continuing operations for fiscal 2025 was $41.75M, a 41.69% increase from fiscal 2024.
- HARMONY BIOSCIENCES HOLDINGS, INC. federal income tax expense (benefit), continuing operations for fiscal 2024 was $29.46M, a 8.31% decline from fiscal 2023.
- HARMONY BIOSCIENCES HOLDINGS, INC. federal income tax expense (benefit), continuing operations for fiscal 2023 was $32.14M.
| Period end | Federal Income Tax Expense (Benefit), Continuing Operations 12 month |
|---|---|
| 2025-12-31 | $41.75M 10-K · filed 2026-02-24 |
| 2024-12-31 | $29.46M 10-K · filed 2026-02-24 |
| 2023-12-31 | $32.14M 10-K · filed 2026-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |